MicroRNA-143 overexpression enhances the chemosensitivity of A172 glioblastoma cells to carmustine.

Autor: Zaer SJ; Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Aghamaali M; Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran. aghamaali@guilan.ac.ir., Najafi S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Hosseini SS; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Amini M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Doustvandi MA; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Mozammel N; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Mokhtarzadeh AA; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ahad.mokhtarzadeh@gmail.com.
Jazyk: angličtina
Zdroj: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Jul 15. Date of Electronic Publication: 2024 Jul 15.
DOI: 10.1007/s00210-024-03287-1
Abstrakt: As an aggressive malignancy, glioblastoma multiforme (GBM) is the most common type of brain tumor. The existing treatments have shown limited achievement in increasing the overall survival of patients. Therefore, identifying the key molecules involved in GBM will provide new potential therapeutic targets. Carmustine is an alkylating agent used as a supplementary therapeutic option for GBM. However, the extensive use of carmustine has been limited by uncertainty about its efficacy. MicroRNAs (miRNAs) are essential in post-transcriptional gene regulation. Many aberrantly expressed miRNAs have been detected in various types of human cancer, including GBM. In this study, we evaluated the potential therapeutic effect of miR-143 in combination with carmustine on GBM cells. A172 cells were transfected with miR-143 mimics and then treated with carmustine. To assess the cell viability, apoptosis induction, and cell cycle progression, the MTT assay, Annexin V/PI apoptosis assay, and flow cytometry were used, respectively. Furthermore, qRT-PCR assay was applied to evaluate the expression level of genes related to apoptosis. The obtained results evidenced that miR-143 transfection could promote the sensitivity of A172 cells to carmustine and enhance carmustine-induced apoptosis via modulating the expression levels of Caspase-3, Caspase-9, Bax, and Bcl-2. Also, our results revealed that combination therapy could effectively diminish cell cycle progression in A172 cells. In conclusion, these results confirmed that miR-143 could enhance carmustine-mediated suppression of cell proliferation and improve the chemosensitivity of A172 cells to this chemotherapeutic agent. Therefore, miR-143 combination therapy may be a promising GBM treatment approach.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: